Skip to main content

Compare Stocks

Date Range: 

 Protara TherapeuticsAxcella HealthApplied Genetic TechnologiesX4 PharmaceuticalsVoyager Therapeutics
SymbolNASDAQ:TARANASDAQ:AXLANASDAQ:AGTCNASDAQ:XFORNASDAQ:VYGR
Price Information
Current Price$8.79$3.41$3.76$8.04$4.47
52 Week RangeBuyBuyBuyBuyHold
MarketRank™
Overall Score1.91.61.51.81.5
Analysis Score3.53.43.53.53.2
Community Score2.72.83.02.82.6
Dividend Score0.00.00.00.00.0
Ownership Score2.51.70.81.71.7
Earnings & Valuation Score0.60.00.01.30.0
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyHold
Consensus Price Target$44.00$16.13$17.58$18.00$12.14
% Upside from Price Target400.57% upside372.87% upside367.64% upside123.88% upside171.51% upside
Trade Information
Market Cap$98.70 million$128.63 million$160.75 million$139.77 million$168.64 million
Beta1.171.532.330.531.8
Average Volume122,83882,6192,589,401113,005575,729
Sales & Book Value
Annual RevenueN/AN/A$2.45 millionN/A$104.39 million
Price / SalesN/AN/A65.61N/A1.62
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value($21.67) per share$2.61 per share$2.76 per share$10.37 per share$2.68 per share
Price / BookN/AN/A1.36N/A1.67
Profitability
Net Income$-14,990,000.00$-59,040,000.00$-45,890,000.00$-52,810,000.00$-43,600,000.00
EPSN/A($3.55)($2.17)($4.63)($1.21)
Trailing P/E Ratio0.00N/AN/AN/AN/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/AN/AN/A-60.61%
Return on Equity (ROE)-45.45%-79.03%-73.06%-47.06%-66.46%
Return on Assets (ROA)-41.09%-54.77%-53.25%-35.89%-17.92%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/A0.28%0.17%0.24%N/A
Current Ratio42.99%22.66%5.27%10.19%3.65%
Quick Ratio42.99%22.66%5.27%10.19%3.65%
Ownership Information
Institutional Ownership Percentage83.11%66.77%57.88%67.76%78.79%
Insider Ownership Percentage45.70%10.40%7.50%4.90%23.90%
Miscellaneous
Employees27598372177
Shares Outstanding11.23 million37.72 million42.75 million17.38 million37.73 million
Next Earnings Date7/30/2021 (Estimated)8/4/2021 (Estimated)N/A7/29/2021 (Estimated)8/9/2021 (Estimated)
OptionableNot OptionableNot OptionableOptionableNot OptionableOptionable
SourceHeadline
Voyager Therapeutics Vectorized Anti-Tau Antibody Shows Encouraging Preclinical Data In CNS DisordersVoyager Therapeutics' Vectorized Anti-Tau Antibody Shows Encouraging Preclinical Data In CNS Disorders
finance.yahoo.com - May 12 at 4:40 PM
Voyager Therapeutics Presents New Preclinical Data Showing Reduction of Pathological Tau with ...Voyager Therapeutics Presents New Preclinical Data Showing Reduction of Pathological Tau with ...
apnews.com - May 12 at 11:40 AM
Analysts Set Expectations for Voyager Therapeutics, Inc.s Q3 2022 Earnings (NASDAQ:VYGR)Analysts Set Expectations for Voyager Therapeutics, Inc.'s Q3 2022 Earnings (NASDAQ:VYGR)
americanbankingnews.com - May 12 at 7:42 AM
Ping An Completes $200 Million First Close of Voyager Partners Fintech and Digital Health FundPing An Completes $200 Million First Close of Voyager Partners Fintech and Digital Health Fund
prnewswire.co.uk - May 12 at 6:39 AM
Nasas Voyager 1 spacecraft detects eerie hum outside our solar systemNasa's Voyager 1 spacecraft detects eerie 'hum' outside our solar system
mirror.co.uk - May 11 at 10:51 PM
NASAs Voyager 1 detects faint, monotone hum beyond our solar systemNASA's Voyager 1 detects faint, monotone hum beyond our solar system
msn.com - May 11 at 5:50 PM
NASAs Voyager 1 Probe Detects Gentle Rain of Plasma Activity in Interstellar SpaceNASA's Voyager 1 Probe Detects 'Gentle Rain' of Plasma Activity in Interstellar Space
msn.com - May 11 at 12:50 PM
Voyager Therapeutics (NASDAQ:VYGR) Issues Quarterly  Earnings Results, Beats Estimates By $0.06 EPSVoyager Therapeutics (NASDAQ:VYGR) Issues Quarterly Earnings Results, Beats Estimates By $0.06 EPS
americanbankingnews.com - May 11 at 12:18 PM
Voyager Therapeutics’ Novel Capsids Demonstrate Robust Delivery Across the Blood Brain Barrier, Widespread CNS Transduction in Non-Human PrimatesVoyager Therapeutics’ Novel Capsids Demonstrate Robust Delivery Across the Blood Brain Barrier, Widespread CNS Transduction in Non-Human Primates
finance.yahoo.com - May 11 at 7:49 AM
Voyager Therapeutics: Q1 Earnings SnapshotVoyager Therapeutics: Q1 Earnings Snapshot
nhregister.com - May 10 at 8:01 AM
Voyager Therapeutics Announces First Quarter 2021 Financial Results and Corporate UpdatesVoyager Therapeutics Announces First Quarter 2021 Financial Results and Corporate Updates
finance.yahoo.com - May 10 at 8:01 AM
NASDAQ:VYGR Long Term Investor Notice: Investigation over Possible Wrongdoing at Voyager Therapeutics, Inc.NASDAQ:VYGR Long Term Investor Notice: Investigation over Possible Wrongdoing at Voyager Therapeutics, Inc.
sbwire.com - May 5 at 12:25 PM
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Expected to Announce Quarterly Sales of $4.79 MillionVoyager Therapeutics, Inc. (NASDAQ:VYGR) Expected to Announce Quarterly Sales of $4.79 Million
americanbankingnews.com - May 1 at 3:18 AM
Scottish CBD brand Voyager set to list on Aquis Stock Exchange Growth MarketScottish CBD brand Voyager set to list on Aquis Stock Exchange Growth Market
globalcosmeticsnews.com - April 30 at 1:14 AM
What Kind Of Shareholders Hold The Majority In Voyager Therapeutics, Inc.s (NASDAQ:VYGR) Shares?What Kind Of Shareholders Hold The Majority In Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Shares?
finance.yahoo.com - April 29 at 8:14 PM
-$0.71 Earnings Per Share Expected for Voyager Therapeutics, Inc. (NASDAQ:VYGR) This Quarter-$0.71 Earnings Per Share Expected for Voyager Therapeutics, Inc. (NASDAQ:VYGR) This Quarter
americanbankingnews.com - April 29 at 8:34 AM
2021 Chrysler Voyager, Dodge Charger and Jeep® Wrangler Claim Kelley Blue Book 5-Year Cost to Own Honors2021 Chrysler Voyager, Dodge Charger and Jeep® Wrangler Claim Kelley Blue Book 5-Year Cost to Own Honors
prnewswire.com - April 28 at 1:36 PM
Voyager Therapeutics Announces Upcoming Data Presentations at the American Society of Gene and Cell Therapy Virtual 2021 Annual MeetingVoyager Therapeutics Announces Upcoming Data Presentations at the American Society of Gene and Cell Therapy Virtual 2021 Annual Meeting
finance.yahoo.com - April 28 at 8:24 AM
NASA’s ‘New Voyager?’ 7 Things To Know About The 50-Year ‘Interstellar Probe’ Mission To Burst Our ‘Cosmic Bubble’NASA’s ‘New Voyager?’ 7 Things To Know About The 50-Year ‘Interstellar Probe’ Mission To Burst Our ‘Cosmic Bubble’
forbes.com - April 27 at 11:04 PM
Voyager Announces Extension of Early Tender Date and Extension of its Previously Announced Exchange Offer and Consent SolicitationVoyager Announces Extension of Early Tender Date and Extension of its Previously Announced Exchange Offer and Consent Solicitation
apnews.com - April 27 at 1:03 PM
Strength Seen in Voyager Therapeutics (VYGR): Can Its 16.5% Jump Turn into More Strength?Strength Seen in Voyager Therapeutics (VYGR): Can Its 16.5% Jump Turn into More Strength?
msn.com - April 27 at 1:03 PM
Voyager Therapeutics Inc. [VYGR] moved up 16.49: Why It’s ImportantVoyager Therapeutics Inc. [VYGR] moved up 16.49: Why It’s Important
dbtnews.com - April 27 at 1:03 PM
FDA says Voyager can trek on as it removes trial hold for Huntington’s gene therapy testFDA says Voyager can trek on as it removes trial hold for Huntington’s gene therapy test
fiercebiotech.com - April 27 at 8:03 AM
Voyager Therapeutics Sees Unusually High Options Volume (NASDAQ:VYGR)Voyager Therapeutics Sees Unusually High Options Volume (NASDAQ:VYGR)
americanbankingnews.com - April 27 at 6:56 AM
Voyager Therapeutics, Inc. (NASDAQ:VYGR): A Disaster In The Making Or A Gold Mine?Voyager Therapeutics, Inc. (NASDAQ:VYGR): A Disaster In The Making Or A Gold Mine?
marketingsentinel.com - April 26 at 7:57 PM
DateCompanyBrokerageAction
4/26/2021Protara TherapeuticsOppenheimerLower Price Target
10/19/2020Protara TherapeuticsCowenInitiated Coverage
7/29/2020Protara TherapeuticsGuggenheimInitiated Coverage
1/22/2020Protara TherapeuticsLADENBURG THALM/SH SHInitiated Coverage
3/20/2021Axcella HealthWedbushReiterated Rating
11/26/2020Axcella HealthChardan CapitalReiterated Rating
11/18/2020Axcella HealthRoth CapitalInitiated Coverage
10/26/2020Axcella HealthSVB LeerinkReiterated Rating
10/14/2020Axcella HealthJPMorgan Chase & Co.Initiated Coverage
9/25/2020Axcella HealthB. RileyInitiated Coverage
8/12/2020Axcella HealthThe Goldman Sachs GroupReiterated Rating
7/30/2020Axcella HealthPiper SandlerInitiated Coverage
7/9/2020Axcella HealthBTIG ResearchLower Price Target
3/8/2021Applied Genetic TechnologiesStifel NicolausInitiated Coverage
2/2/2021Applied Genetic TechnologiesHC WainwrightBoost Price Target
11/20/2020Applied Genetic TechnologiesBerenberg BankReiterated Rating
6/22/2020Applied Genetic TechnologiesCantor FitzgeraldInitiated Coverage
1/24/2020Applied Genetic TechnologiesJanney Montgomery ScottReiterated Rating
1/9/2020Applied Genetic TechnologiesBMO Capital MarketsBoost Price Target
12/17/2020X4 PharmaceuticalsBrookline Capital ManagementInitiated Coverage
11/9/2020X4 PharmaceuticalsCanaccord GenuityLower Price Target
3/26/2020X4 PharmaceuticalsCitigroupLower Price Target
4/26/2021Voyager TherapeuticsMorgan StanleyLower Price Target
3/1/2021Voyager TherapeuticsRobert W. BairdReiterated Rating
12/23/2020Voyager TherapeuticsRaymond JamesDowngrade
11/10/2020Voyager TherapeuticsWells Fargo & CompanyDowngrade
5/13/2020Voyager TherapeuticsNomuraReiterated Rating
3/30/2020Voyager TherapeuticsNomura SecuritiesLower Price Target
(Data available from 5/13/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.